UnitedHealth Group confirmed Thursday the corporate is dealing with legal and civil investigations from the Division of Justice (DOJ) associated to its Medicare billing practices.
The well being care big stated in a securities submitting and subsequent assertion it has begun complying with formal legal and civil requests.
UnitedHealth’s inventory was additionally down rather less than 4 % on Thursday.
“The Company has a long record of responsible conduct and effective compliance,” UnitedHealth stated in its submitting. “Independent CMS audits confirm that the Company’s practices are among the most accurate in the industry, and, following a decade-long civil challenge by the Department to aspects of our Medicare Advantage business, a court-appointed Special Master concluded there was no evidence to support claims of wrongdoing.”
UnitedHealth stated it has launched its personal initiative to conduct third celebration critiques of “policies, practices, and associated processes and performance metrics for risk assessment coding, managed care practices, and pharmacy services.”
The disclosure marks the primary time the corporate has acknowledged the existence of any DOJ investigations, and it comes after a sequence of Wall Avenue Journal articles in latest months introduced the small print to gentle.
The corporate stated it “proactively” reached out to the DOJ after reviewing media experiences in regards to the company’s investigations.
The Journal reported in February that the DOJ launched a civil investigation into whether or not the corporate inflated diagnoses to set off additional funds to its Medicare Benefit (MA) plans, that are privately run insurance policy reimbursed by the federal authorities. The outlet first reported on the legal Medicare fraud probe in Might.
UnitedHealth is the biggest insurer within the MA market.
Thursday’s announcement comes forward of its second-quarter earnings name on July 29 and will mark a shift in technique below new CEO Stephen Hemsley, who took over in Might after Andrew Witty immediately stepped down.
The corporate has skilled a tumultuous 12 months that included suspending its 2025 earnings forecast, partly as a consequence of greater medical prices for brand spanking new MA plan enrollees.
